| l-Arginine Supplementation in Peripheral Arterial Disease: No Benefit and Possible Harm AM Wilson, R Harada, N Nair, N Balasubramanian, JP Cooke Circulation 116 (2), 188-195, 2007 | 284 | 2007 |
| β2-Microglobulin as a biomarker in peripheral arterial disease: proteomic profiling and clinical studies AM Wilson, E Kimura, RK Harada, N Nair, B Narasimhan, XY Meng, ... Circulation 116 (12), 1396-1403, 2007 | 226 | 2007 |
| Circulating miRNA as novel markers for diastolic dysfunction N Nair, S Kumar, E Gongora, S Gupta Molecular and cellular biochemistry 376, 33-40, 2013 | 117 | 2013 |
| Cardiac myosin binding protein-C is a potential diagnostic biomarker for myocardial infarction S Govindan, A McElligott, S Muthusamy, N Nair, D Barefield, JL Martin, ... Journal of molecular and cellular cardiology 52 (1), 154-164, 2012 | 91 | 2012 |
| Epidemiology and pathogenesis of heart failure with preserved ejection fraction N Nair Reviews in cardiovascular medicine 21 (4), 531-540, 2020 | 89 | 2020 |
| Asymmetric dimethylarginine correlates with measures of disease severity, major adverse cardiovascular events and all-cause mortality in patients with peripheral arterial disease AM Wilson, DS Shin, C Weatherby, RK Harada, MK Ng, N Nair, J Kielstein, ... Vascular medicine 15 (4), 267-274, 2010 | 77 | 2010 |
| Commonality between depression and heart failure N Nair, C Farmer, E Gongora, GJ Dehmer The American journal of cardiology 109 (5), 768-772, 2012 | 68 | 2012 |
| Current and future challenges in therapy for antibody-mediated rejection N Nair, T Ball, PA Uber, MR Mehra The Journal of heart and lung transplantation 30 (6), 612-617, 2011 | 62 | 2011 |
| Pathophysiology and management of neurocardiogenic syncope MD Nandini Nair, FA Padder, BK Kantharia The American journal of managed care 9, 327-334, 2003 | 60 | 2003 |
| Cardiac myosin-binding protein-C is a critical mediator of diastolic function CW Tong, NA Nair, KM Doersch, Y Liu, PC Rosas Pflügers Archiv-European Journal of Physiology 466, 451-457, 2014 | 48 | 2014 |
| Stem cell therapy in heart failure: Where do we stand today? N Nair, E Gongora Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1866 (4), 165489, 2020 | 42 | 2020 |
| Cardiovascular changes in menopause AR Nair, AJ Pillai, N Nair Current cardiology reviews 17 (4), 2021 | 37 | 2021 |
| Oxidative stress and cardiovascular aging: interaction between NRF-2 and ADMA N Nair, E Gongora Current cardiology reviews 13 (3), 183-188, 2017 | 34 | 2017 |
| Increased oncogenic potential of ErbB is associated with the loss of a COOH-terminal domain serine phosphorylation site. SJ Theroux, C Taglienti-Sian, N Nair, JL Countaway, HL Robinson, ... Journal of Biological Chemistry 267 (12), 7967-7970, 1992 | 34 | 1992 |
| Long-term immunosuppression and malignancy in thoracic transplantation: where is the balance? N Nair, E Gongora, MR Mehra The Journal of Heart and Lung Transplantation 33 (5), 461-467, 2014 | 33 | 2014 |
| Heart failure in chemotherapy-related cardiomyopathy: Can exercise make a difference? N Nair, E Gongora BBA clinical 6, 69-75, 2016 | 31 | 2016 |
| Can microRNAs emerge as biomarkers in distinguishing HFpEF versus HFrEF? N Nair, S Gupta, IX Collier, E Gongora, K Vijayaraghavan International journal of cardiology 175 (3), 395-399, 2014 | 30 | 2014 |
| Correlations of GDF-15 with sST2, MMPs, and worsening functional capacity in idiopathic dilated cardiomyopathy: Can we gain new insights into the pathophysiology? N Nair, E Gongora Journal of circulating biomarkers 7, 1849454417751735, 2018 | 24 | 2018 |
| Protein tyrosine kinase activities of the epidermal growth factor receptor and ErbB proteins: correlation of oncogenic activation with altered kinetics N Nair, RJ Davis, HL Robinson Molecular and cellular biology 12 (5), 2010-2016, 1992 | 19 | 1992 |
| Thrombolytics in VAD management—a single-center experience N Nair, AA Schmitt, EM Rau, S Anders, D Sandler, TB Icenogle IJC Heart & Vasculature 11, 49-54, 2016 | 18 | 2016 |
